Home
Companies
Catalysts
Deep Dives
Hepcludex
bulevirtide
FILED
Drug Profile
Modality
Peptide
Route
SC
Therapy Area
Infectious Disease
Peak Sales Est
$1000M
Formulations
[{"id":"hepcludex-sc","route":"SC","setting":"PATIENT_SELF","frequency":"Once daily","is_primary":tr
Companies
GILD
(ORIGINATOR)
100%
Mechanism: NTCP receptor blocker
Expert:
Entry inhibitor targeting sodium taurocholate co-transporting polypeptide (NTCP), the functional receptor for HDV and HBV.
Everyday:
Blocks the receptor that hepatitis delta virus uses to enter liver cells.
Targets: ["NTCP"]
Programs (1)
Indication
Stage
Key Study
Regional Status
Chronic hepatitis delta
FILED
MYR301
[{"stage":"APPROVED","region":"EU","approval_date":"2020-07-31"}]
Upcoming Catalysts (1)
Hepcludex - Chronic Hepatitis Delta - FDA Approval
2026
Data from Supabase · Updated 2026-03-24